1492 Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

1492 Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Buy	+66,997	New	+$1.39M	0.43%	64

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

1492 Capital Management's SNDX Position: Q2 2026 in Review

1492 Capital Management opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 66,997 shares worth $1.46M. The stake represents 0.43% of the portfolio and ranks #64 among its holdings.

242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

1492 Capital Management held 66,997 shares of Syndax Pharmaceuticals worth $1.46M as of Q2 2026.
Syndax Pharmaceuticals was a new 1492 Capital Management position in Q2 2026.
Syndax Pharmaceuticals made up 0.43% of 1492 Capital Management's portfolio in Q2 2026, its #64 holding.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.